ABUSArbutus Biopharma Corporation
Price
-2.7%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality shaky, nothing alarming, growth steady, the market undecided.
Charts
As reported to the SEC, without any scoring.
Arbutus Biopharma Corporation (ABUS) reported revenue of $1.0M in Q2 2026 (quarter ended Jun 30, 2026), down 91% from the same quarter a year earlier. That came with net loss of $5.1M. For the full year FY2025, revenue was $14M (+128% year on year) and net income −$34M. Its largest product in Q2 2026 was License at $632K, 62% of the disclosed total, well ahead of Collaboration And Contracts at 20%. The next results filing is expected around Nov 12, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 21, 2026On August 21, 2026, Arbutus Biopharma Corporation (the “Company”) issued a press release announcing its plans to launch a modified “Dutch auction” tender offer to purchase up to US$230 million in value of its common shares, at a price ranging from US$5.00 to US$5.75.Other event · Form 8-K
- Aug 12, 2026Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update.Earnings release · press release
- Jul 16, 2026In March 2025, Arbutus Biopharma Corporation (“Arbutus” or the “Company”) entered into an agreement (the “RSV Agreement”) with Genevant Sciences GmbH (“Genevant”) that provided that Arbutus would be entitled to any award of damages in, or proceeds from the settlement of, certain patent litigation against Moderna, Inc. …Material agreement terminated · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $1.0MThe company’s own SEC segment disclosure.
- License$632.0K62%
- Collaboration And Contracts$202.0K20%
- Non-Cash Royalty$180.0K18%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.